BOSTON, Jan. 14, 2025 /PRNewswire/ — Haemonetics (NYSE:) Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has completed its previously announced sale of its entire blood assets to GVS, SpA (“GVS”), one of the world’s leading manufacturers of filtration solutions for applications in the healthcare and life sectors. In connection with the closing of this transaction, GVS acquired Haemonetics’ portfolio of proprietary whole blood collection, processing and filtration solutions, along with Haemonetics’ manufacturing facility in Covina, California where some of these products are manufactured. , and related equipment and assets are located. at the Haemonetics manufacturing facility in Tijuana, Mexico.

The transaction consists of a total cash consideration of up to $67.8M, including $45.3M upfront after giving effect to certain customary adjustments, and up to $22.5M in contingent revenue over the next four years. The Company intends to use the proceeds from this transaction for general corporate purposes and to further invest in growth initiatives. Haemonetics will provide additional details about the financial impact of this transaction on its fiscal year 2025 guidance during its third quarter earnings call, scheduled for February 6, 2025on 8:00 AM ET.

Haemonetics Blood Center The business will continue to manufacture and provide customers with a full line of apheresis solutions for automated blood collection. It includes tools and disposable kits that support different apheresis collections, including platelets, plasma and red cells, and ensure the smooth operation of the blood center.

ABOUT HAEMONETIKS

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve the care of patient and reduce health care costs. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current results. fact and may be identified by the use of words such as “could,” “will,” “must,” “could,” “want,” “expects,” “plans,” “expects,” “believes,” “estimates,” “projects,” “predicts,” “forecasts,” “estimates,” “potential” and other words of similar meaning in connection with statements about, among others matter, (i) the anticipated benefits of Haemonetics arising from the completion of the transaction; (ii) statements about Haemonetics’ strategies, positioning, resources, capabilities and expectations for future performance; and (iii) the assumptions underlying or relating to any such statement. Such forward-looking statements are not intended to predict or guarantee actual results, performance, events or conditions and may not be realized because they are based on current projections, plans, intentions, beliefs, expectations, estimates and assumptions of Haemonetics and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described in the forward-looking statements as a result of these risks and uncertainties.

Factors that could influence or contribute to the inaccuracy of forward-looking statements or cause actual results to differ materially from anticipated or desired results may include, without limitation, the failure to achieve expectations benefits of the transaction, including from not achieving any commercial milestone required to receive all or part of the additional consideration, or the transaction having an unexpected effect; Haemonetics’ ability to accurately forecast the demand for its products and products is improved and develop strategies to meet the markets successfully; and the impact of competitive products and pricing and technical innovations that could make products marketed or under development by Haemonetics obsolete. These and other factors are identified and described in more detail in Haemonetics’ filings US Securities and Exchange Commission. Haemonetics does not intend to update these forward-looking statements.